Voyager Therapeutics, Inc.
VYGR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.14 | -0.18 | 0.16 | -0.01 |
| FCF Yield | -11.38% | -18.84% | -19.55% | -4.47% |
| EV / EBITDA | 0.00 | -5.03 | -4.88 | -8.07 |
| Quality | ||||
| ROIC | 0.00% | -12.40% | -10.84% | -11.12% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.11 | 1.00 | 1.22 | 0.42 |
| Growth | ||||
| Revenue 3-Year CAGR | -41.74% | -39.77% | -29.46% | 25.06% |
| Free Cash Flow Growth | 9.05% | 10.86% | -162.55% | 47.98% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.11 | 0.97 | 0.74 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 21.45 | 43.70 | 29.34 | 64.38 |